BiomX Inc. (PHGE)

BiomX, Inc. underwent a 1-for-19 reverse stock split on November 25, 2025. The Phase 2b BX004 trial was discontinued on December 8, 2025. A $3.0 million private placement was announced on December 29, 2025. Positive topline Phase 2 results for BX211 were reported. Patient dosing in the Phase 2b trial of BX004 began in July 2025. In November 2025, BiomX reported a net loss of $9.2 million for Q3 2025. The company's share price experienced a significant decline of 87.46% from January 2, 2025, to December 31, 2025.

BiomX, Inc. does not currently have commercial products, so traditional demand seasonality is not applicable. The company's financial performance is primarily driven by clinical trial milestones, regulatory feedback, and financing events.

BiomX, Inc. is a clinical-stage microbiome company focused on developing phage cocktails to target harmful bacteria associated with chronic diseases, operating within the Biotechnology & Medical Research industry. Its product pipeline includes BX004 for chronic pulmonary infections, BX211 (now BX011) for diabetic foot osteomyelitis, BX005 for atopic dermatitis, BX003 for inflammatory bowel disease, and a colorectal cancer program. As a clinical-stage company, BiomX generates revenue through R&D collaborations and licensing agreements.

BiomX, Inc. is headquartered in Ness Ziona, Israel.

BiomX's brand reputation has been influenced by clinical trial progress and financial activities. Positive news included the reporting of positive topline Phase 2 results for its BX211 program. The discontinuation of the Phase 2b BX004 trial and news of the company filing for insolvency could negatively impact its reputation.

BiomX, Inc. has a notable institutional ownership presence, with major holders including Deerfield Management Company, L.P., and others, ranging from approximately 32.01% to 40.57% of the stock. Insider ownership is between 1.33% and 3.00%. As of November 2025, CEO Jonathan Solomon held a direct ownership stake of 18.81%.